SGHT Sight Sciences, Inc.
$9.03▲ +0.11%
Healthcare
Other
After hours
$9.03▲ +0.00%
Oct 27, 4:42 PM ET
Volume 266.1K
Avg Volume (10D) 272.3K
Key Metrics & Fundamentals
Market Cap
$497.44M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.38 - 9.71
% vs 50 MA
5.94%
% vs 200 MA
51.76%
RSI-14
57.2
MACD Histogram
+0.0200
Beta (1Y vs SPY)
1.67
Free Cash Flow
-$5.68M
Gross Rev
$23.39M
Gross Profit
$21.37M
EBITDA
-$3.71M
COGS
$2.01M
Operating Exp
$25.26M
Operating Income
-$3.89M
EBIT
-$3.89M
Pretax Income
-$4.42M
Net Income
-$4.45M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire · Oct 21, 2026 4:05 PM ET
HC Wainwright Initiates Coverage on Sight Sciences With Buy Rating, $14 Price Target
MT Newswires · Oct 15, 2026 7:40 AM ET
Sight Sciences (SGHT) Stock Gets Fair Value Boost After Analyst Target Increases
Simply Wall St. · Oct 8, 2026 8:18 AM ET
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
GlobeNewswire · Oct 1, 2026 7:05 AM ET
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
GlobeNewswire · Sep 1, 2026 4:05 PM ET
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Zacks · Aug 20, 2026 11:54 AM ET
Sector Update: Healthcare Stocks Gain Wednesday Afternoon
MT Newswires · Aug 19, 2026 1:26 PM ET
Sector Update: Healthcare Stocks Higher in Wednesday Trading
MT Newswires · Aug 19, 2026 9:43 AM ET
Sight Sciences Gets US FDA Label Expansion for TearCare Dry Eye Treatment
MT Newswires · Aug 19, 2026 7:45 AM ET
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
GlobeNewswire · Aug 19, 2026 7:05 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SGHT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.